OptimizeRx (OPRX) Short-term Investments (2022 - 2023)
OptimizeRx recorded quarterly Short-term Investments of $53.6 million in Q3 2023, up 1.3% quarter-over-quarter from $52.9 million in Q2 2023, and up 43.11% year-over-year from $37.5 million in Q3 2022.
OptimizeRx's Short-term Investments history runs 2 years deep, the most recent figure standing at $53.6 million for Q3 2023.
- In Q3 2023, Short-term Investments rose 43.11% year-over-year to $53.6 million; the TTM figure through Sep 2023 stood at $53.6 million (up 43.11% YoY), while the FY2022 annual figure was $55.9 million, changed N/A from the prior year.
- Short-term Investments came in at $53.6 million for Q3 2023 at OptimizeRx, up from $52.9 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $57.3 million in Q1 2023 to a low of $37.5 million in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn |
| 10 | OptimizeRx | 101.31 Mn | 81.14 Mn | 15.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 53.62 Mn |
| Jun 30, 2023 | 52.93 Mn |
| Mar 31, 2023 | 57.26 Mn |
| Dec 31, 2022 | 55.93 Mn |
| Sep 30, 2022 | 37.47 Mn |